Get started
Author

Ippokratis Korantzis

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
2023 · Myung-Ju Ahn, Byoung Chul Cho, et al. · New England Journal of Medicine · 670
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2025 · Giannis Mountzios, Longhua Sun, et al. · New England Journal of Medicine · 348
PDF
Use of Proteins as Biomarkers and Their Role in Carcinogenesis
2014 · Paul Zarogoulidis, Kosmas Tsakiridis, et al. · Journal of Cancer · 60
PDF
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
2011 · Christos A Papadimitriou, Pavlos Papakostas, et al. · BMC Medicine · 51
PDF
OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up
2024 · J. Sands, B.C. Cho, et al. · Journal of Thoracic Oncology · 28
PDF
Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS)
2012 · Vassiliki Kotoula, Dimitrios Krikelis, et al. · BMC Cancer · 27
PDF
Prognostic Significance of Low HER2 Expression in Patients With Metastatic Hormone Receptor-positive Breast Cancer Treated With First Line CDK4/6 Inhibitors: A Greek Multicenter Real-world Data Analysis
2022 · GEORGE DOUGANIOTIS, GEORGE KESISIS, et al. · Cancer Diagnosis & Prognosis · 24
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
2026 · Hanny Al-Samkari, César Muñoz, et al. · New England Journal of Medicine · 22
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry
2022 · Giannis Mountzios, David Planchard, et al. · JTO Clinical and Research Reports · 21
PDF
Clinical outcomes for patients with liver-limited metastatic colorectal cancer: Arguing the case for specialist hepatobiliary multidisciplinary assessment
2016 · K. Thillai, D. Repana, et al. · European Journal of Surgical Oncology · 20
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem
2016 · Dimitrios C. Ziogas, Dionysios Papadatos-Pastos, et al. · European Journal of Gastroenterology & Hepatology · 19
Delayed malignant melanoma recurrence simulating primary ovarian cancer: Case report
2008 · Anastasios Boutis, Rosalia Valeri, et al. · World Journal of Surgical Oncology · 14
PDF
Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.
2012 · Ippokratis Korantzis, Konstantine T Kalogeras, et al. · PubMed · 13
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort
2026 · Oliver Illini, Anna-Carina Hund, et al. · Journal of Thoracic Oncology · 9
PDF
437TiP Trial in progress: A phase III global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator’s choice in chemorefractory metastatic colorectal cancer (CodeBreaK 300)
2022 · D. Paez, F. Meriggi, et al. · Annals of Oncology · 7
Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis.
2026 · Giannis S. Mountzios, Byoung Chul Cho, et al. · Journal of Clinical Oncology · 6
508MO Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study
2023 · L. Paz-Ares, M-J. Ahn, et al. · Annals of Oncology · 5
PDF
LBA92 Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study
2023 · L. Paz-Ares, M-J. Ahn, et al. · Annals of Oncology · 5
PDF
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer
2024 · Myung-Ju Ahn, Byoung Chul Cho, et al. · Future Oncology · 4
PDF
Genetic Predisposition to Male Breast Cancer: A Case Series
2022 · ANGELA APESSOS, KONSTANTINOS AGIANNITOPOULOS, et al. · Anticancer Research · 4
TLR4 single nucleotide polymorphisms and thrombosis risk in patients with myeloproliferative disorders
2007 · M. Speletas, K. Liadaki, et al. · Thrombosis Research · 4
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
2026 · Maurice Pérol, Tatsuya Yoshida, et al. · New England Journal of Medicine · 3
Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study)
2025 · Ippokratis Korantzis, Anna Koumarianou, et al. · BMC Cancer · 2
PDF
LBA100 Detailed safety analysis of DeLLphi-304: The first phase III study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer
2025 · M.H.H. Schuler, G. Mountzios, et al. · Annals of Oncology · 2
PDF
Romiplostim for chemotherapy-induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT).
2025 · Hanny Al-Samkari, Cesar Munoz, et al. · Journal of Clinical Oncology · 2
Works count: 56
Citation count: 1,378
H-index: 13
I10-index: 13
Year
Topic
Type